Charles F. Wagner Jr. - 17 Mar 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP & Chief Financial Officer
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
17 Mar 2023
Net transactions value
-$592,786
Form type
4
Filing time
21 Mar 2023, 16:21:13 UTC
Previous filing
14 Mar 2023
Next filing
28 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale $106,027 -360 -0.67% $294.52 53,019 17 Mar 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale $231,617 -784 -1.5% $295.43 52,235 17 Mar 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale $71,112 -240 -0.46% $296.30 51,995 17 Mar 2023 Direct F1, F2, F5
transaction VRTX Common Stock Sale $107,312 -360 -0.69% $298.09 51,635 17 Mar 2023 Direct F1, F2, F6
transaction VRTX Common Stock Sale $71,899 -240 -0.46% $299.58 51,395 17 Mar 2023 Direct F1, F2, F7
transaction VRTX Common Stock Sale $4,818 -16 -0.03% $301.13 51,379 17 Mar 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022.
F2 Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $294.52 (range $293.98 to $294.81).
F4 Open market sales reported on this line occurred at a weighted average price of $295.43 (range $295.09 to $295.97).
F5 Open market sales reported on this line occurred at a weighted average price of $296.30 (range $296.14 to $296.45).
F6 Open market sales reported on this line occurred at a weighted average price of $298.09 (range $297.65 to $298.48).
F7 Open market sales reported on this line occurred at a weighted average price of $299.58 (range $299.09 to $300.06).